Fluoroquinolones vs macrolides in the treatment of Legionnaires disease

Chest

Volumn 128, Issue 3, 2005, Pages 1401-1405

  Sabrià, Miquel ^a   Pedro Botet, María Luisa ^a   Gómez, Joaquín ^b   Roig, Jorge ^c   Vilaseca, Blanca ^a   Sopena, Nieves ^a   Baños, Victor ^b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITY OF MURCIA   (Spain)

^c HOSPITAL NOSTRA SENYORA DE MERITXELL   (Andorra)

Author keywords

Fluoroquinolones; Legionella; Legionnaires disease; Macrolides; Pneumonia

Indexed keywords

BACTERIAL ANTIGEN; CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIOSTASIS; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG INDICATION; FEMALE; FEVER; HOSPITALIZATION; HUMAN; LEGIONELLA PNEUMOPHILA; LEGIONNAIRE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 24944476483     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.3.1401     Document Type: Article

References (35)

1. Meyer RD, Finegold SM. Legionnaires' disease. Annu Rev Med 1980; 31:219-232
2. Hays JH, Hinthorn DR, Chonko A, et al. Failure of oral erythromycin therapy for Legionnaires' disease in a renal transplant recipient. South Med J 1981; 74:1422-1423
3. Mercatello A, Frappaz D, Robert D, et al. Failure of erythromycin/ rifampicin treatment of Legionella pneumonia. J Infect 1985; 10:282-283
4. Rudin JC, Evans TL, Wing EJ. Failure of erythromycin in treatment of Legionella micdadei pneumonia. Am J Med 1984; 76:318-320
5. Stout J, Arnold B, Yu VL. Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristine/dalfopristin and erythromycin against Legionella species by intracellular susceptibility testing in HL-60 cells. J Antimicrob Chemother 1998; 41:289-291
6. Stout J, Arnold B, Yu VL. Comparative activity of ciprofloxacin, ofloxacin, levofloxacin, and erythromycin against Legionella species by broth microdilution and intracellular susceptibility testing in HL-60 cells. Diagn Microbiol Infect Dis 1998; 30:37-43
7. Dubois J, St-Pierre C. In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species. Clin Microbiol Infect 1999; 5:205-212
8. Edelstein PH, Edelstein MAC. In vitro activity of the ketolide HMR 3647 (TU6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother 1999; 43:90-95
9. Schülin T, Wennersten CB, Ferraro MJ, et al. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother 1998; 42:1520-1523
10. Walz A, Nichterlein T, Hof H. Excellent activity of newer quinolones on Legionella pneumophila in J 774 macrophages. Zentralbl Bakteriol 1997; 285:431-439
11. Edelstein PH, Edelstein MAC. WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages. Antimicrob Agents Chemother 1989; 33:2132-2136
12. Edelstein PH, Edelstein MAC, Lehr KH, et al. In vitro activity of levofloxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. J Antimicrob Chemother 1996; 37:117-126
13. Saito A, Sawatari K, Fukuda Y, et al. Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs. Antimicrob Agents Chemother 1985; 28:15-20
14. Stout JE, Arnold B, Yu VL. Comparative activity of ciprofloxacin, ofloxacin, levofloxacin, and erythromycin against Legionella species by broth microdilution and intracellular susceptibility testing in HL-60 cells. Diagn Microbiol Infect Dis 1998; 30:37-43
15. Wynkel A, Toupance O, Melin JP, et al. Traitement des légionelloses par ofloxacine chez le transplant renal: abscence d'interférence avec la ciclosporine A. Presse Med 1991; 20:291-293
16. Unertl KE, Lenhart FP, Forst H, et al. Ciprofloxacin in the treatment of legionellosis in critically ill patients including those cases unresponsive to erythromycin. Am J Med 1989; 87(Suppl):128S-131S
17. Barrio M, Ramos M, Page MA, et al. Brote epidémico de neumonía por Legionella pneumophila en Murcia 2001. Rev Clin Esp 2002; 202(Suppl):126-127
18. Fernandez-Avilés F, Batlle M, Ribera JM, et al. Legionella spp. pneumonia in patients with hematologic diseases: a study of 10 episodes from a series of 67 cases of pneumonia. Hematologica 1999; 84:474-475
19. Stout JE, Yu VL. Current concepts: legionellosis. N Engl J Med 1997; 337:682-687
20. Parker MM, Macher AM, Shelhamer JH, et al. Unresponsiveness of Legionella bozemanii pneumonia to erythromycin administration despite in vitro susceptibility. Am Rev Respir Dis 1983; 128:95.5-956
21. Sabrià M, Yu VL. Legionella species (Legionnaires' disease). In: Yu VL, Weber R, Raoult D, eds. Antimicrobial therapy and vaccines. 2nd ed. New York, NY: Apple Trees Productions, 2002; 395-417
22. Manzor O, Majithia D, Saravolatz L. In vitro activities of seven quinolones and two macrolides against Legionella isolates [abstract no E2284]. In: Program and Abstracts of the 1999 International Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA: American Society for Microbiology, 1999
23. Sanchez-Conde M, Pérez-Molina JA, Moreno L, et al. Treatment with levofloxacin of community-acquired pneumonia caused by Legionella spp [abstract no P846]. In: Program and Abstracts of the 2001 European Congress of Clinical Microbiology and Infectious Diseases. Istanbul, Turkey: European Society of Clinical microbiology and Infectious Diseases, 2001
24. Pedro-Botet ML, Sabrià M, Sopena N, et al. Legionnaires' disease and HIV infection. Chest 2003; 124:543-547
25. Edelstein PH. Antimicrobial chemotherapy for Legionnaires' disease: a review. Clin Infect Dis 1995; 21:5265-5276
26. Salord JM, Matsiota-Bernard P, Staikowsky F, et al. Unsuccessful treatment of Legionella pneumophila infection with a fluoroquinolone. Clin Infect Dis 1993; 17:518-519
27. Kurz RW, Graninger W, Egger TP, et al. Failure of treatment of Legionella pneumophila with ciprofloxacin. J Antimicrob Chemother 1988; 22:389-391
28. Drusano G, Lebro MT, Cars O, et al. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Microbiol Infect 1998; 4:2S27-2S41
29. Baltch AL, Smith RP, Franke MA, et al. Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila. Antimicrob Agents Chemother 1998; 42:3153-3156
30. Pedro-Botet ML, Sabria-Leal M, Sopena N, et al. Role of immunosuppression in the evolution of Legionnaires' disease. Clin Infect Dis 1998; 26:14-19
31. Heath CH, Grove DI, Looke DF. Delay in appropriate therapy of Legionella pneumonia associated with increased mortality. Eur J Clin Microbiol Infect Dis 1996; 15:286-290
32. Gacouin A, Le Toulzo Y, Lavoue S, et al. Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy. Intensive Care Med 2002; 28:686-691
33. Dournon E, Mayaud C, Wolff M, et al. Comparison of the activity of three antibiotic regimens in severe Legionnaires' disease. J Antimicrob Chemother 1990; 26(Suppl):129-139
34. Edelstein PH. Antimicrobial chemotherapy for Legionnaires' disease: time for a change. Ann Intern Med 1998; 129:328-330
35. Roig J, Rello J. Legionnaires' disease: a rational approach to therapy. J Antimicrob Chemother 2003; 51:1119-1129